SCHEMBL24673819

SCHEMBL24673819

CCCc1ccc(CNCC(C)C)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.44
S1PR2 O95136 2/20 0.44
S1PR4 O95977 2/20 0.44
S1PR1 P21453 2/20 0.44
S1PR3 Q99500 2/20 0.44
LMNA P02545 1/20 0.42
OPRM1 P35372 2/20 0.42
OPRK1 P41145 2/20 0.42
ALDH1A1 P00352 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42
CA2 P00918 2/20 0.41
KMT2A Q03164 1/20 0.40
HRH4 Q9H3N8 1/20 0.40
HRH3 Q9Y5N1 1/20 0.40
LPL P06858 1/20 0.39
LIPG Q9Y5X9 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
PLK1 P53350 1/20 0.39
KCNH2 Q12809 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25923261 0.87 L3MBTL1 (0.53) L3MBTL1S1PR2S1PR4S1PR1S1PR3
SCHEMBL25479303 0.85 LMNA (0.57) L3MBTL1LMNAOPRM1OPRK1ALDH1A1
SCHEMBL2242597 0.82 TAAR1 (0.52) L3MBTL1OPRM1OPRK1ALDH1A1CYP1A2
SCHEMBL22856392 0.81 L3MBTL1 (0.46) L3MBTL1S1PR2S1PR4S1PR1S1PR3
SCHEMBL22794506 0.81 TAAR1 (0.50) L3MBTL1S1PR2S1PR4S1PR1S1PR3
SCHEMBL23945721 0.79 L3MBTL1 (0.45) L3MBTL1LMNAOPRM1OPRK1ALDH1A1
SCHEMBL12659603 0.79 CHRM2 (0.53) L3MBTL1OPRM1OPRK1ALDH1A1CYP1A2
SCHEMBL25883717 0.78 L3MBTL1 (0.44) L3MBTL1S1PR2S1PR4S1PR1S1PR3
SCHEMBL23665811 0.78 OPRK1 (0.43) L3MBTL1LMNAOPRM1OPRK1ALDH1A1
SCHEMBL170986 0.78 LMNA (0.64) L3MBTL1LMNAALDH1A1CYP2D6KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220340570-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2022-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220340570-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 L3MBTL1 1394/4885S1PR2 2608/4885S1PR4 2262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.